Politicians urge Obama to allow public review of IP provisions in TPP

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Politicians urge Obama to allow public review of IP provisions in TPP

Six members of US Congress have written to US President Barack Obama expressing concern that "secret" negotiations over intellectual property in the Trans Pacific Partnership (TPP) Agreement benefit pharmaceutical companies at the expense of public health.

The six Democrats - Jan Schakowsky (Illonois), Michael Michaud (Maine), Rosa DeLauro (Conneticut), George Miller (California), Barbara Lee (California) and Peter Welch (Vermont) - said the current proposals would have "profound and long-lasting consequences".

In the letter, sent yesterday, the Members urged Obama not to make any final trade agreements "that affect critical health issues" until members of the public and Congress have had the opportunity to review the provisions and provide input.

In particular, they argued that proposed provisions relating to data exclusivity, patent registration and procedure and enforcement would "delay generic competition and increase the price of medicine" and lead to "preventable illnesses and deaths".

"Certainly, trade negotiations conducted behind closed doors are not the place to make changes that would have such profound consequences for patents and veterans, as well as state and federal budgets," they wrote.

Although the TPP negotiations were meant to have been conducted in secret, whistleblowing website WikiLeaks has released several documents which suggest the US is exerting "great pressure" on other nations to adopt stricter IP policies. In the latest release, yesterday, WikiLeaks published two leaked documents that suggest that the US is isolated in its positions on many IP policies.

more from across site and SHARED ros bottom lb

More from across our site

The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Gift this article